823 related articles for article (PubMed ID: 27793053)
1. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
2. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML; Athar M; Ferguson JE; Varambally S
Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
[TBL] [Abstract][Full Text] [Related]
3. Targeting EZH2 in cancer therapy.
Yamagishi M; Uchimaru K
Curr Opin Oncol; 2017 Sep; 29(5):375-381. PubMed ID: 28665819
[TBL] [Abstract][Full Text] [Related]
4. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
Li B; Chng WJ
J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
[TBL] [Abstract][Full Text] [Related]
5. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
6. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
Italiano A
Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746
[TBL] [Abstract][Full Text] [Related]
7. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
Gautam N; Kaur M; Kaur S
J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
[TBL] [Abstract][Full Text] [Related]
8. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
[TBL] [Abstract][Full Text] [Related]
9. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
11. MUC1-C activates EZH2 expression and function in human cancer cells.
Rajabi H; Hiraki M; Tagde A; Alam M; Bouillez A; Christensen CL; Samur M; Wong KK; Kufe D
Sci Rep; 2017 Aug; 7(1):7481. PubMed ID: 28785086
[TBL] [Abstract][Full Text] [Related]
12. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA; Lange CA
Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.
Tsang DP; Cheng AS
J Gastroenterol Hepatol; 2011 Jan; 26(1):19-27. PubMed ID: 21175789
[TBL] [Abstract][Full Text] [Related]
14. Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers.
Wan Z; Jiang H; Li L; Zhu S; Hou J; Yu Y
Bioorg Med Chem; 2020 Apr; 28(7):115379. PubMed ID: 32098708
[TBL] [Abstract][Full Text] [Related]
15. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
16. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
[TBL] [Abstract][Full Text] [Related]
17. Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?
Jangal M; Lebeau B; Witcher M
Expert Opin Ther Targets; 2019 Jul; 23(7):565-578. PubMed ID: 31177918
[No Abstract] [Full Text] [Related]
18. Polycomb Repressive Complex 2 in Oncology.
Guo Y; Yu Y; Wang GG
Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
[TBL] [Abstract][Full Text] [Related]
19. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
Sashida G; Iwama A
Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
[TBL] [Abstract][Full Text] [Related]
20. EZH2 inhibitors: a patent review (2014-2016).
Stazi G; Zwergel C; Mai A; Valente S
Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
